Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma

Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.

Authors

Noa Biran¹, Elli Gourna Paleoudis², Rena Feinman³, David H Vesole¹, Joshua Zenreich, Shuqi Wang⁴, Jaeil Ahn⁴, Meena Bansal¹, Scott Rowley¹, Michele Donato¹, Andrew L Pecora¹, Joshua Richter⁵, Palka Anand¹, Laura McBride¹, Kristin Ivanovski¹, Robert Korngold³, David S Siegel¹

Affiliations

¹ John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
² Office of Research Administration, Hackensack Meridian Health, Hackensack, New Jersey, USA.
³ Center for Discovery & Innovation, Hackensack Meridian Health, Institute for Multiple Myeloma, Hackensack, New Jersey, USA.
⁴ Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, District of Columbia, USA.
⁵ Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 34435374
DOI: 10.1002/ajh.26333

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dexamethasone / adverse effects
Dexamethasone / therapeutic use*
Follow-Up Studies
Humans
Lenalidomide / adverse effects
Lenalidomide / therapeutic use*
Multiple Myeloma / drug therapy*
Multiple Myeloma / therapy
Stem Cell Transplantation
Transplantation, Autologous

Substances

Antibodies, Monoclonal, Humanized
Dexamethasone
pembrolizumab
Lenalidomide